芪苈强心胶囊佐治缺血性心肌病左心衰竭的临床价值  

The clinical value of Qiliqiangxin capsule in assistant treatment of left heart failure in patients with ischemic cardiomyopathy

作　　者：王生平[1] 冯胜红 冯永生[1] 任静[1] 方翔[1] 

机构地区：[1]四川省达州市中西医结合医院(达州市第二人民医院)心血管内科,635000

出　　处：《疑难病杂志》2015年第12期1284-1287,共4页Chinese Journal of Difficult and Complicated Cases

摘　　要：目的探讨芪苈强心胶囊佐治缺血性心肌病左心衰竭患者的临床疗效及对心功能、生活质量的影响。方法入选2012年7月—2015年2月门诊及住院缺血性心肌病患者120例,按照就诊顺序随机分成对照组和治疗组各60例。2组均按冠心病二级预防及慢性心力衰竭治疗指南给予规范化治疗,治疗组加用芪苈强心胶囊,每次4粒,每天3次,疗程为6个月。疗程结束后评价治疗效果,检测血浆N末端脑钠肽前体(NT-pro BNP)及红细胞分布宽度(RDW),复查心脏左室射血分数(LVEF)、左室舒张末期内径(LVEDD),进行6 min步行试验(6MWD)以及明尼苏达生活量表(MRSM)评分。结果治疗6个月后,治疗组总有效率为86.67%,明显高于对照组的70.00%(x^2=4.910,P<0.05)。与治疗前比较,2组治疗后NT-pro BNP、RDW、LVEF、LVEDD明显改善,MRSM评分明显降低,6MWD明显增加,且治疗组LVEF、LVEDD、MRSM评分、6 MWD改善优于对照组(P<0.05)。结论芪苈强心胶囊在缺血性心肌病患者的治疗中,可明显改善心功能,提高患者生活质量,在一定程度上减少患者心血管事件的发生,值得临床推广应用。Objective To investigate the clinical curative effect of Qiliqiangxin capsule in the treatment of ischemic cardiomyopathy with left heart failure and influence on heart function and quality of life.Methods From July 2012 to February 2015,120 patients with ischemic cardiomyopathy were selected.The patients were randomly divided into control group and treatment group.According to the secondary prevention of coronary heart disease and chronic heart failure treatment guidelines,they were given standard treatment,the treatment group added Qiliqiangxin capsule,4 capsules each time,3 times a day,treatment for 6 months.At the end of the course,the treatment effect were evaluated,plasma N-lerminal pro brain natriuretic peptide precursor（NT-proBNP） and red cell distribution width（KDW） were detected,the hearts left ventricle ejection fraction（LVEF）,left ventricular end diastolic diameter（LVEDD）,6 min walking test（6MWD） and Minnesota Life Scale（MRSM） score were followed up.Results After 6 months of treatment,the total efficiency of treatment group was 86.67%,which was significantly higher than the control group（70.00%,x-2=4.910,P〈0.05）.Compared with before treatment,NT-ProBNP level,RDW,LVEF,LVEDD were improved obviously after treatment in both of the two groups,MRSM score decreased significantly,6 MWD significantly increased,and treatment group＇s LVEF,LVEDD,MRSM score,6 MWD were better than control group（P〈0.05）.Conclusion The Qiliqiangxin capsule in the treatment of patients with ischemic cardiomyopathy can significantlv improve the cardiac function,improve the quality of life of patients,in a certain extent,reduce the occurrence of cardiovascular events,it is worthy of clinical application.

关 键 词：芪苈强心胶囊 缺血性心肌病 N末端脑钠肽前体 红细胞分布宽度 心脏功能 生活质量 

分 类 号：R542.2[医药卫生—心血管疾病]